Business Wire

OR-GUROBI-OPTIMIZATION

18.8.2020 15:02:14 CEST | Business Wire | Press release

Share
River Logic Selects the Gurobi Optimizer as its Preferred Mathematical Optimization Solver

Gurobi Optimization, LLC and River Logic, Inc today announced that River Logic has chosen the Gurobi Optimizer as the preferred mathematical optimization solver for its prescriptive analytics platform. By embedding the Gurobi Optimizer in its platform, River Logic expects its customers to take full advantage of the capabilities of this best-of-breed solver, leading in many cases to faster solve times and increased profit opportunities.

After a thorough evaluation and selection process, River Logic – which had been using another commercial solver as a component of its prescriptive analytics platform for many years – decided to switch to the Gurobi Optimizer.

River Logic’s Chief Technology Officer Peter Bull said: "We are tremendously excited to announce a long-term partnership with Gurobi to harness the power of their optimization solver technology with River Logic’s unique prescriptive analytics cloud SaaS application. River Logic, now together with Gurobi, is at the forefront of driving prescriptive analytics solutions across an increasing number of industries and organizations, helping them to transform their business operations and capabilities."

There were three main reasons behind River Logic’s decision to switch to the Gurobi Optimizer:

  • Performance : The Gurobi Optimizer is the world’s fastest and most powerful mathematical optimization solver, which is constantly setting new industry standards in terms of speed and solution quality. With the Gurobi Optimizer as a key component of River Logic’s solutions, River Logic customers – many of whom are business users without a background in mathematical programming – will see a substantial reduction in the time it takes to optimally solve complex business problems.
  • Vision : Gurobi’s R&D team – which is comprised of the leading experts in the mathematical optimization software industry – is fully focused on developing and delivering the best mathematical optimization solver technology. This goes hand-in-hand with River Logic’s commitment to providing the best planning and decision-support solutions to its global customers. With Gurobi and River Logic’s commitment to continuous improvement and cutting-edge innovation, River Logic customers can be assured that they are using the state-of-the-art solver – today and in the future.
  • Support : Gurobi’s Support team – which is made up of PhD-level mathematical optimization specialists – is dedicated to providing world-class support for customers using the Gurobi Optimizer. River Logic’s technical team and customers will have access to Gurobi’s Support team – who will be there to assist them and make sure they are able to utilize mathematical optimization as effectively as possible in River Logic’s platform.

Gurobi’s Chief Revenue Officer Duke Perrucci commented: “We are thrilled to have the Gurobi Optimizer power River Logic's suite of first-class optimization applications. Our relentless focus on innovation will allow River Logic's customers to tackle the world's most complex problems at speed and with confidence.”

About Gurobi Optimization

Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability.

As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.

Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit www.gurobi.com or call +1 713 871 9341.

About River Logic

River Logic is on a mission to ensure companies across the globe drive maximum value with every decision, no matter how complex the business problem or how quickly markets shift. As a global innovator in advanced analytics, River Logic offers optimization solutions purpose-built for business users rather than data scientists. Its cloud-based solutions enable enterprise-wide optimization through a revolutionary cloud experience that offers rapid scenario collaboration, data management, workflows, scalability, and more. Companies are finally able to align decisions around complex trade-offs with overarching business objectives without sacrificing speed, agility, and flexibility. For more information, please visit www.riverlogic.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release

The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye